VIDEO: Ibrutinib plus rituximab yields superior PFS vs. FCR in previously untreated CLL
Click Here to Manage Email Alerts
In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, talked about results from the phase 3 FLAIR study presented at ASH Annual Meeting and Exposition.
The study showed that ibrutinib plus rituximab had superior PFS compared with combination fludarabine, cyclophosphamide and rituximab (FCR) in patients with previously untreated chronic lymphocytic leukemia. In addition, there was no difference in OS between the ibrutinib-based regimen and FCR, according to Davids.
“This is very different from what we saw in the ECOG 1912 study where there was a statistically significant overall survival advantage with the ibrutinib-based regimen,” he said. “I do think that calls into question a little bit whether for young, fit patients — particularly with mutated IGHV — we should be using ibrutinib as a default.”
Collapse
Hillmen P, et al. Abstract 642. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Click Here to Manage Email Alerts